Recursion Signs a Worldwide License Agreement with Takeda to Develop TAK-733 for Hereditary Cancer Syndrome

Shots:

• Recursion to get exclusive WW rights to develop and commercialize TAK-733 for the treatment of a hereditary cancer syndrome and related areas of oncology
• Recursion will utilize its automated drug discovery platform to discover the potential of TAK-733 by testing 200+ potential molecules from Takeda’s library against cancers carrying mutations
• TAK-733 is identified as a potential treatment for a hereditary tumor syndrome using Recursion’s approach for creating cellular models of diseases with inactive genes

Click here ­to­ read full press release/ article | Ref: Business wire | Image: Recursion